Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward